SAB Biotherapeutics, Inc.

NASDAQ:SABS

Biotechnology

Healthcare
$3.20 -0.53%

-$0.02 today

Market cap
$288.28M
Beta
0.53
P/E (TTM)
3.0
EPS (TTM)
-$0.16
52W Low $1.85High $5.15

Volume 0.89M

Average 0.76M

SABS EBITDA Margin

EBITDA as a percentage of revenue.

SAB Biotherapeutics, Inc.NASDAQ: SABS

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin not reported for Q2 FY2026

Context

  • EBITDA Margin widened in 0 of the last 2 fiscal years.
  • FY2024 was the lowest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMJun 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2024
-2192.5%
Year-over-year change
-489.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How SABS compares with its peers on the latest reported figures

SABS Competitors Peer median
EBITDA Margin for SABS and competitors
Company Period LTM level YoY 3-year change
QTTBQ32 Bio Inc.LTM Mar 202641.2% —+616.4 pp
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026-30.6% +743.3 pp+212.8 pp
SABSSAB Biotherapeutics, Inc.FY2025— ——
ANTXAN2 Therapeutics, Inc.FY2025— ——
BOLDBoundless Bio, Inc.FY2025— ——
Peer median (excluding SABS) 5.3%+743.3 pp+414.6 pp

Competitors are the stored peer set for SABS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue60.88M23.9M2.24M1.32M0
Cost of Revenue1.65M3.29M3.75M4.79M3.08M
Gross Profit59.22M20.61M(1.51M)(3.47M)(3.08M)
Gross Margin97.3%86.2%-67.3%-262.4%—
Research & Development57.18M36.44M16.52M30.16M34.35M
Selling, General & Admin17.09M16.38M23.8M9.28M14.6M
Operating Expenses72.62M49.53M36.57M39.44M45.87M
Depreciation & Amortization1.65M3.29M3.75M4.79M3.08M
EBITDA(15.2M)(15.12M)(38.13M)(28.99M)16.6M
EBITDA Margin-25.0%-63.3%-1703.1%-2192.5%—
Operating Income(13.39M)(28.92M)(38.08M)(42.91M)(48.95M)
Operating Margin-22.0%-121.0%-1700.5%-3244.9%—
Interest Income23.12K71.07K584.97K1.29M1.43M
Interest Expense294.46K301.58K315.28K318.4K240.66K
Other Income / Expenses(3.75M)10.2M(4.12M)8.81M62.23M
Income Before Tax(17.15M)(18.72M)(42.19M)(34.11M)13.27M
Pre-Tax Margin-28.2%-78.3%-1884.5%-2579.0%—
Income Tax Expense025.63K000
Net Income(17.15M)(18.74M)(42.19M)(34.11M)13.27M
Net Margin-28.2%-78.4%-1884.5%-2579.0%—
EPS (Basic)(3.94)(4.31)(7.64)(3.68)0.22
EPS (Diluted)(6.30)(4.31)(7.64)(3.68)(0.79)
Weighted Avg Shares4.35M4.35M5.52M9.26M19.31M
Weighted Avg Shares (Diluted)2.73M4.35M5.52M9.26M61.34M

SAB Biotherapeutics, Inc.

NASDAQ:SABS

Intrinsic Alpha fair value

Locked

Current Price

$3.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.